Diakonos Oncology Corporation, a clinical stage immuno-oncology company, announced that the U.S. Food and Drug Administration has granted Fast Track designation for the Company’s unique dendritic cell vaccine, DOC1021.
Diakonos Oncology Corporation, a clinical stage immuno-oncology company, announced that the U.S. Food and Drug Administration has granted Fast Track designation for the Company’s unique dendritic cell vaccine, DOC1021.